Company news

Kymera Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference

May 18, 2025

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

May 8, 2025

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

May 8, 2025

Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

May 6, 2025

Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

April 23, 2025

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

April 21, 2025

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

April 8, 2025

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

February 26, 2025

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

February 25, 2025

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

February 19, 2025

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

January 13, 2025

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

January 6, 2025

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

October 30, 2024

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

October 23, 2024

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

October 22, 2024

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium

October 22, 2024

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

October 8, 2024

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

September 24, 2024

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

August 20, 2024

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

August 18, 2024

Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

August 6, 2024

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

July 30, 2024

Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day

July 8, 2024

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

July 7, 2024

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

June 13, 2024

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

May 31, 2024

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

May 22, 2024

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

May 21, 2024

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

May 13, 2024

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

May 7, 2024

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update

May 1, 2024

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

April 24, 2024

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

April 7, 2024

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

March 7, 2024

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

February 21, 2024

Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22

February 14, 2024

Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference

January 30, 2024

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs

January 8, 2024

Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 8, 2024

Kymera Therapeutics Announces Pricing of $275 Million Public Offering

January 4, 2024

R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

January 3, 2024

Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024

January 1, 2024

Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4

December 12, 2023

Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting

December 9, 2023

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi

December 6, 2023

Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine

November 12, 2023

Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting

November 1, 2023

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

November 1, 2023

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi

October 26, 2023

Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2

October 25, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 36 decks. Every deck is listed under its year.